- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | ProKidney GAAP EPS of -$0.13, revenue of $0.2M | 1 | Seeking Alpha | ||
| 12.05. | PROKIDNEY CORP. Loss At -$16.73 Mln In Q1 | 1 | RTTNews | ||
| 12.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | ProKidney Reports First Quarter 2025 Financial Results and Business Highlights | 345 | GlobeNewswire (Europe) | Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional... ► Artikel lesen | |
| 12.05. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 31.03. | PROKIDNEY CORP. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.03. | ProKidney GAAP EPS of -$0.62 | 2 | Seeking Alpha | ||
| 17.03. | PROKIDNEY CORP. Full Year Loss Increases | - | RTTNews | ||
| 17.03. | ProKidney Reports Full Year 2024 Financial Results and Business Highlights | 164 | GlobeNewswire (Europe) | Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing... ► Artikel lesen | |
| 21.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11.24 | ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting | 169 | GlobeNewswire (Europe) | FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed... ► Artikel lesen | |
| 09.08.24 | ProKidney Reports Business Updates and Second Quarter 2024 Financial Results | 299 | GlobeNewswire (Europe) | Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,238 | 0,00 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives | Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1 -high, VEGF-naïve and liver metastasis subgroups... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,080 | -100,00 % | Enveric Biosciences, Inc.: Enveric Biosciences Participating in BIO-Europe Spring | Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 0,470 | +2,49 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer | WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases... ► Artikel lesen | |
| REPARE THERAPEUTICS | 1,395 | -1,06 % | Repare Therapeutics Inc. - 8-K, Current Report | ||
| BIOATLA | 0,384 | +2,37 % | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen | |
| RELMADA THERAPEUTICS | 0,540 | +1,89 % | Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,210 | -1,79 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| BOUNDLESS BIO | 1,030 | -3,74 % | Boundless Bio, Inc. - 8-K, Current Report | ||
| PEPGEN | 1,160 | -9,38 % | PepGen Inc. hält Jahreshauptversammlung, wählt Direktoren und bestätigt Wirtschaftsprüfer | ||
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen |
Das Unternehmen PROKIDNEY CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,034 (-4,68 %) liegt der Kurs bei 0,689 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.